⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8813718 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL8814070 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL8810940 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL8813115 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL5912856 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL23578504 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL17260735 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL8811768 | 1.00 | TSHR (0.46) | — | |
| SCHEMBL557134 | 0.97 | — | — | |
| SCHEMBL23119378 | 0.93 | FAAH (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | disclosed |
| CN-104024241-B | Uracil derivatives and their use for medical purposes | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | disclosed |
| US-9040516-B2 | Uracil derivative and use thereof for medical purposes | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140357641-A1 | IP receptor agonist heterocyclic compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2802582-A1 | FUSED DIHYDROPYRIDO [2,3 -B]PYRAZINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8835475-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140179670-A1 | URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20100234345-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-16 | — | — | US | disclosed |
| CN-101765593-A | 2-iminoisothiazole derivatives as cannabinoid receptor ligands | ABBOTT LAB | 2010-06-30 | — | — | CN | disclosed |
| WO-2010054024-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090023789-A1 | N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | US | disclosed |
| US-20060270721-A1 | EP4 receptor agonist, compositions and methods thereof | HAN YONGXIN | 2006-11-30 | — | — | US | disclosed |
| US-7109223-B2 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma | MERCK & CO. INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060154899-A1 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma | MERCK FROSST CANADA LTD. (CA) | 2006-07-13 | — | — | US | disclosed |
| EP-1545517-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | Merck Frosst Canada & Co. (CA) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019938-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2004-03-11 | — | — | WO | disclosed |